Eli Lilly developed tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management.
Eli Lilly and Company was founded in Indianapolis in 1876 by Colonel Eli Lilly, a pharmaceutical chemist and Union army veteran. The company grew through the production of medicines including insulin, antibiotics, and psychiatric treatments. Its research-based model later made it one of the world’s largest pharmaceutical businesses by market value.
Tirzepatide is a medicine that activates receptors for GIP and GLP-1, hormones involved in blood-sugar regulation and appetite. The US Food and Drug Administration approved Mounjaro for type 2 diabetes in 2022 and Zepbound for chronic weight management in 2023. Eli Lilly is often confused with Novo Nordisk because both became closely associated with injectable diabetes and weight-management medicines, but their leading products and corporate histories are distinct.